Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2005-11-22
pubmed:abstractText
Priorities for developing improved regimens for treatment of latent tuberculosis (TB) infection include (1) developing shorter and/or more intermittently administered regimens that are easier to supervise and (2) developing and evaluating regimens that are active against multidrug-resistant organisms.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10331734, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10421369, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10511409, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10524579, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10732934, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10879539, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-10993565, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-11316634, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-11709328, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12019103, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12045127, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12066961, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12160118, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12543673, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12543692, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12569078, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12588714, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12654841, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12904741, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-12907951, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-14506018, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-14578218, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-14742554, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15024625, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15297274, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15526006, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15690060, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15917523, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-15917524, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-16141439, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-18360951, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-2817579, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-5145008, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-9195099, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-9519950, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-9687408, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-9869570, http://linkedlifedata.com/resource/pubmed/commentcorrection/16151038-9875583
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1073-449X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
172
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1452-6
pubmed:dateRevised
2011-3-24
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
pubmed:affiliation
Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA. enuermb@jhmi.edu
More...